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Background: Identification of cancer stem cells (CSCs) and their behaviors will provide insightful information for
the future control of human cancers. This study investigated CD44 and CD24 cell surface markers as breast cancer
CSC markers in vitro and in vivo.
Methods: Flow cytometry with CD44 and CD24 markers was used to sort breast cancer MCF7 cells for scanning
electron microscopy (SEM), tumor cell invasion assay, and nude mouse xenograft assay.
Results: Flow cytometry assay using CD44 and CD24 markers sorted MCF7 cells into four subsets, i.e., CD44+/CD24-/low,
CD44-/CD24+, CD44+/CD24+, and CD44-/CD24-. The SEM data showed that there were many protrusions on the surface
of CD44+/CD24-/low cells. CD44+/CD24-/low cells had many microvilli and pseudopodia. The CD44+/CD24-/low cells had a
higher migration and invasion abilities than that of the other three subsets of the cells. The in vivo tumor formation
assay revealed that CD44+/CD24- cells had the highest tumorigenic capacity compared to the other three subsets.
Conclusion: CD44 and CD24 could be useful markers for identification of breast CSCs because CD44+/CD24-/low cells
had unique surface ultrastructures and the highest tumorigenicity and invasive abilities.
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Cancer stem cells (CSCs) were originally described in
hematologic malignancies and have the exclusive ability to
self-renew and differentiate into heterogeneous lineages of
tumor cells [1,2]. The concept of CSC theory may change
our perspective with regard to cancer development, pro-
gression, and treatment. CSCs are defined as a small num-
ber of tumor cells that have the ability to generate daughter
tumor cells, self-renew, and maintain tumor phenotypes. In
addition, CSCs are responsible for tumor resistance to
chemo- and radiation therapy, recurrence, and metastasis
[3-6]. Currently, searching for CSC markers is a very hot
topic and some interesting data have been generated. For
example, markers for CSCs of the breast, prostate, colon,
and pancreas have been reported [7-9], but more work
needs to be done. Furthermore, it is evident that the* Correspondence: chinawtj218@163.com
1Department of Radiotherapy, Second Affiliated Hospital of Jilin University,
130021, Changchun, China
Full list of author information is available at the end of the article
© 2013 Yan et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the ordistinguished ultrastructure of cancer cells is linked to the
tumorigenic potential for making tumor diagnoses and
predicting tumor behaviors (such as recurrence, metastasis,
and so on) [10-12]; however, it is unknown whether CSCs
possess their own particular ultrastructure partners. There-
fore, identification of CSCs and understanding of their be-
haviors in human cancer will provide us useful information
for defining the molecular mechanisms of cancer develop-
ment and progression and developing novel treatment
strategies.
In human breast cancer, it has been shown that breast
CSCs have a CD44+/CD24- phenotype [2]. Consistent
with this finding, knockdown of CD44 expression has
been found to induce breast CSCs to differentiate into
regular tumor cells without the capacity to self-renew
(defined as non-CSCs) [13]. Nevertheless, in certain breast
cancer patients, CD44+/CD24- cells are still sensitive to
radiotherapy, suggesting that not all breast CSCs are
radioresistant [14] and that not all CD44+/CD24- cells are
CSCs. Indeed, clinical data have indicated that there is no. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cell prevalence and tumor progression. The prevalence of
a CD44+/CD24-/low tumor cell did not correlate with the
event-free and overall survival and did not affect the tumor
response to different treatment modalities [15,16]. Thus,
further investigation is needed to clarify these two markers
for breast CSCs. In this study, we first sorted breast cancer
cells with these two markers and then analyzed the ultra-
structure of the breast CSC surface in CD44+/CD24-/low
genotypes. Furthermore, we systemically analyzed the
ultrasturcture, invasion capacity, and tumor formation in
breast cancer MCF7 cells with different CD44/CD24 geno-
types. Our findings indicated that CD44+/CD24-/low MCF7
cells with high numbers of microvilli and pseudopodia
have greater tumorigenicity rates and invasive ability.Figure 1 Flow cytometry sorting of MCF7 cells using CD44 and CD24
sorting (FACS) using anti-CD44 and anti-CD24 antibodies. B, Quantification
CD44+/CD24-/low cell type using flow cytometry.Materials and methods
Cell line and culture
The human breast cancer cell line MCF7 was obtained
from the Shanghai Cell Bank (Shanghai, China) and main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
with high glucose and supplemented with 10% fetal calf
serum (FCS), 100 units/ml penicillin, and 100 μg/ml
streptomycin at 37°C in 5% CO2.
Flow cytometry
To sort tumor cells with CD44 and CD24 markers, MCF7
cells were seeded and grown for several days, then washed
with phosphate-buffered saline (PBS), and finally harvested
with 0.05% trypsin/0.025% EDTA. The cells were then de-
tached and washed with PBS containing 2% FCS beforemarkers. A, MCF7 cells were analyzed by fluorescence-activated cell
of the four subsets of MCF7 cells. C, Confirmation of the purity of the
Figure 2 Cell surface ultrastructure of the four different subsets of MCF7 cells. A, CD44+/CD24-/low; B, CD44+/CD24+; C, CD44-/CD24+;
and D, CD44-/CD24-.
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fluorochrome-conjugated monoclonal antibodies against
human CD44 (FITC) and CD24 (PE) or their respective
isotype controls were added to the cell suspensions at a
concentration recommended by the manufacturer andFigure 3 Invasion assay of these four subsets of MCF7 cells. A, Cell nu
subsets of MCF7 cells (Green: CD44+/CD24-/low; Red: CD44-/CD24+; Yellow:
migration distance. D, Images of cell migration distance.incubated on ice in the dark for 20 min. After that, cells
were washed twice with PBS/2% FCS and resuspended in
0.5 ml (per million cells) of PBS/2% FBS for flow
cytometric analysis using a FACSVantage instrument.
Anti-human CD44 FITC (Clone: IM7; 11-0441-82) andmber quantification of invasion. B, Confocal images of these four
CD44+/CD24+; and Blue: CD44-/CD24-). C, Quantification of tumor cell
Table 1 Invasion capacity of these different
MCF7 subtypes
Cell subtypes Invasion cell number n t p
CD44-/CD24+ 126.7 ± 13.33 6 5.77 0.004
CD44+/CD24+ 38.0 ± 3.18 6 20.69 0.000
CD44-/CD24- 194.4 ± 27.77 6 4.21 0.013
CD44+/CD24- 485.7 ± 43.62 6 — —
Table 2 Migration distances of these different
MCF7 subtypes
Cell subtypes Migration distances n t p
CD44-/CD24+ 8664.3 ± 157.12 6 −19.45 0.000
CD44+/CD24+ 12996.2 ± 699.02 6 7.25 0.002
CD44-/CD24- 8764.0 ± 99.62 6 −9.80 0.001—
CD44+/CD24- 20011.0 ± 999.47 6 —
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bodies were obtained from Affymetrix eBioscience (www.
affymetrix.com).
Scanning electron microscopy (SEM)
To detect the ultrastructure of CD44+/CD24-/low breast
CSCs, we performed SEM experiments by directly using
flow cytometry-sorted cells. Briefly, flow cytometry-sorted
cells were seeded onto glass cover slips and fixed in situ
with 2.5% paraformaldehyde in PBS for 2 h at 4°C. Then,
the cells were rinsed in PBS and postfixed with 1% osmium
tetroxide in PBS for 1 h, dehydrated through a graded
ethanol series, stained en bloc during dehydration with a
saturated solution of uranyl acetate in 70% ethanol, and
then embedded in Araldite for the ultrastructural study of
cells using SEM.
Tumor cell invasion assay
Breast cancer MCF7 cells were cultured in complete cell
medium and then stained with anti-CD44-FITC and
anti-CD24-PE antibodies (Miltenyi Biotec, Germany).
After that, the cells were washed twice with cold PBS
and then stained with DAPI before being washed twice
with PBS. Next, these cells were first cultured in serum-
free DMEM overnight. The next day, the cells were de-
tached with trypsin, counted, and added into the top
chambers of Transwell inserts with an 8-μm pore size
filter coated with Matrigel in 24-well plates. In the bot-
tom of the chambers, DMEM containing 20% FCS was
added, and the cells were then cultured for 24 h. At the
end of the experiments, the cells on the top surface of
the filter were removed by using a cotton-swab, and the
cells on the bottom of the filter were fixed with methyl
alcohol and then reviewed and quantified by a laser scan-
ning confocal microscope (FV-1000; Olympus Japan).
Animal experiments
Flow cytometry-sorted cells were collected, washed in
PBS, and then injected into the mammary fat pad of 5-
week-old severe combined immunodeficient (SCID) mice.
Mice were maintained in laminar flow rooms under con-
stant temperature and humidity and received estradiol
supplementation (0.4 mg/kg) every week after cell injec-
tion. Mice were inspected for tumor appearance daily by
observation and palpation for 12 weeks after cell injection.
At the end of the experiments, all mice were sacrificed by
cervical dislocation, and the presence of each tumor nod-
ule was confirmed by necropsy. Experimental protocols
were approved by the Ethics Committee for Animal Ex-
perimentation of the institute.
Statistical analyses
All the in vitro experiments were repeated six times, and
had similar results. Statistical analysis was performedusing SPSS software version 17.0. Statistical significance
was tested by using a two-tailed Student’s t-test. P<0.05
was considered statistically significant.
Results
Sorting breast cancer MCF7 cells using CD44 and
CD24 markers
To obtain putative breast CSCs from MCF7 cell line, we
performed flow cytometry assay using antibodies against
CD44 and CD24 cell surface markers. We obtained four
subtypes of tumor cells (i.e., CD44+/CD24-/low, CD44+/
CD24+, CD44-/CD24+, and CD44-/CD24-; Figure 1). The
percentages of CD44+/CD24-/low, CD44+/CD24+, CD44-/
CD24+, and CD44-/CD24- cells were 3.5%, 79.8%, 15.0%,
and 3.6%, respectively (Figure 1). According to the litera-
ture, the CD44+/CD24-/low cells were breast CSCs (approxi-
mately 3.5%; Figure 1). The purity of this sorted cell type
was further confirmed using flow cytometry. As shown in
Figure 1C, the purity of the CD44+/CD24-/low cell type was
more than 90%.
Detection of the cell surface ultrastructure of flow
cytometry-sorted MCF7 cells
To characterize the ultrastructural features of flow
cytometry-sorted MCF7 cells, we performed SEM experi-
ments. Our data showed that there are numerous protru-
sions on the surface of CD44+/CD24-/low cells (Figure 2A).
These cells also showed many microvilli and pseudopodia
compared to the other three cell subsets (Figure 2). In
contrast, CD44+/CD24+ cells showed a rough surface with
several but less abundant protrusions and fewer pseu-
dopodia on the surface compared to CD44+/CD24-/low
cells (Figure 2B). Again, CD44-/CD24+ cells showed a
smooth surface with fewer protrusions and pseudopodia
(Figure 2C), while CD44-/CD24- cells showed a smooth
surface with fewer protrusions and no pseudopodia
Table 3 In vivo tumor xenograft assay of these four
subsets of MCF7 cells
MCF7 cell
subset
Tumor formation with the indicated
number of cells
1×103 1×104 1×105
CD44+/CD24-/low 1/6 4/6 6/6
CD44-/CD24+ 0/6 0/6 0/6
CD44+/CD24+ 0/6 0/6 2/6
CD44-/CD24- 0/6 0/6 0/6
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ultrastructure is quite different among these four sub-
types of MCF7 cells.Invasion capacity of breast cancer MCF7 cells with
different expressions of CD44 and CD24 markers
To examine the invasion capacity of these four different
subsets of MCF7 cells, we first labeled them with different
colors (Green: CD44+/CD24-/low; Red: CD44-/CD24+, Yel-
low: CD44+/CD24+; and Blue: CD44-/CD24-). A laser con-
focal microscope randomly selected five fields (×400) to
count the number of these four subsets of cells that invaded
through the basement membrane (Figure 3). The numbers
of CD44+/CD24-/low, CD44+/CD24+, CD44-/CD24+, and
CD44-/CD24- cells that invaded through the basement
membrane were 485.7 ± 43.628, 194.4 ± 27.778, 126.7 ±
13.333, and 38.0 ± 3.189, respectively (Figure 3A). The
number of CD44+/CD24-/low cells that invaded through the
basement membrane was significantly higher than that of
the other three subsets (Figure 3B). The migration distances
of CD44+/CD24-/low, CD44+/CD24+, CD44-/CD24+, and
CD44-/CD24- cells were 20011.0 ± 999.476 nm, 12996.3 ±
699.028 nm, 8664.5 ± 157.124 nm, and 8764.6 ± 99.620
nm, respectively (Table 1, Figure 3C, D). Thus, the migra-
tion distance of CD44+/CD24-/low was significantly longer
than that of the other three subsets (Table 2, Figure 3C, D).
These results suggest that CD44+/CD24-/low cells have the
highest invasion capacity compared to the other three sub-
sets of MCF7 cells.Figure 4 In vivo tumor xenograft assay of these four subsets MCF7 ce
and D, CD44-/CD24-.Xenograft formation and growth capacity among these
four subtypes of CD44 and CD24-expressing breast
cancer cells in nude mice
To compare the tumor-initiating capability of different
MCF7 cell subsets, we injected the four flow cytometry-
sorted cell subsets at different cell numbers (1×103,
1×104, and 1×105) into the mammary left fat pad of
nonobese diabetic (NOD)/SCID mice. All mice were ob-
served for 3 months for tumor formation and growth
(Table 3 and Figure 4). Briefly, 13 days after the injec-
tion of 1×103 CD44+/CD24-/low cells, a palpable tumor
formed in one of six mice. Meanwhile, after the injection
of 1×104 CD44+/CD24-/low cells, tumors formed in four
of six mice at 11 ± 1.2 days. Furthermore, an injection
of 1×105 CD44+/CD24-/low cells formed tumors in all six
mice at 9 ± 2.3 days. In contrast, of the other three
subsets of MCF7 cells, even with an injection of 1×105
cells, only CD44+/CD24+ cells formed tumors in two of
six mice at day 21 and none of the CD44-/CD24- and
CD44-/CD24+ cells were able to form tumors. These data
suggest that CD44+/CD24- cells have the highest tumori-
genic capacity compared to the other three cell subsets.Discussion
Breast CSCs, like all other CSCs, have been suggested to
contribute to tumor development and progression
[17,18]. Thus, identification of breast CSCs is very im-
portant not only for understanding the mechanism of
breast cancer but also providing novel strategies for its
successful treatment. Previous studies have used specific
molecular markers and ultrastructures to identify and
isolate breast CSCs [19-22]. It is well known that the
surface ultrastructure of cancer cells is unique and im-
portant for cancer development [23,24], since the surface
ultrastructure of cells can predict cell-cell and cell-matrix
contact, movability, and adhesion ability. However, to date,
information regarding the cell surface ultrastructure of
breast CSCs is limited. Herein, in this study, we analyzed
the surface ultrastructure of different subsets of MCF7
cells after sorting by the known breast CSC markerslls. A, CD44+/CD24-/low; B, CD44+/CD24+; C, CD44-/CD24+;
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breast cancer cells showed numerous protrusions on the
cell surface and had many microvilli and pseudopodia,
indicating such ultrastructures may contribute to higher
tumorigenesis and invasion ability. The association be-
tween surface marker and surface ultrastructure of CSCs
is quite interesting, i.e., CSCs might have a special surface
ultrastructure and provide valuable information to identify
CSCs and biological significance. Further understanding
of these features could help us to develop a novel clinical
cancer-targeted therapy. However, at the current stage,
due to lack of standard CSC surface ultrastructure data, it
is difficult to quantify the CSCs pseudopodia. We will de-
velop a methodology to quantify them in the near future.
The CD44 antigen, encoded by the CD44 gene on
chromosome 11, is a cell-surface glycoprotein involved
in cell–cell interactions, cell adhesion, and migration [25].
CD44 has been reported as a cell surface marker for some
breast and prostate CSCs, but it is associated with an in-
creased survival duration of epithelial ovarian cancer pa-
tients [5,26]. Likewise, CD24 is encoded by the CD24 gene
and is also a cell adhesion molecule [27]. The expression
of CD24 is associated with tumor development and plays
a critical role in various cancer metastases [28,29]. How-
ever, more recently, researchers in the field of CSCs have
used these two proteins as markers to identify breast CSCs
with high CD44 expression and negative or low CD24 ex-
pression [2,3]. In this study, we also sorted breast cancer
MCF7 cells using these two markers to obtain four
subpopulations of MCF7 cells. Consistent with previous
studies, we found that the CD44+/CD24-/low population
had high tumorigenic potential and invasion capacity.
Because in vivo tumor formation is the gold standard
for identification of CSCs [30], our current data further
confirmed that CD44+/CD24- cells have the highest tu-
morigenic capacity compared to the other three subsets of
MCF7 cells; however, the tumorigenic capacity of CD44+/
CD24- cells was not as strong as that found in a previous
report [2]. In our current study, only one of six mice
formed a breast cancer xenograft with 1×103 cells/injection.
However, our current data also showed that CD44+/CD24+
cells formed tumor xenografts in two of six mice after the
injection of 1×105 cells. This finding indicates that CD24 is
not as good as CD44 as a marker for the identification of
breast CSCs. We further analyzed the tumor weight and
size in different groups; however, we did not observe any
significant differences among them, indicating that CSCs
might contribute to cancer initiation but not tumor
progression.
Conclusion
In summary, this study systematically investigated the
ability of CD44 and CD24 proteins as markers to identify
breast CSCs among MCF7 cells using flow cytometry tosort the MCF7 cells with these two proteins into four
subsets. Moreoever, CD44+/CD24- cells showed a unique
surface ultrastructure by SEM and had the highest tumor-
igenic potential in tumor cell invasion and nude mouse
xenograft assays. Further studies will determine whether
CD44 directly contributes to the unique surface ultra-
structure and tumorigenic capacity.
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